Page last updated: 2024-09-04

cyc 202 and Lymphoma, B-Cell

cyc 202 has been researched along with Lymphoma, B-Cell in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bertoni, F; Catapano, CV; Gaidano, G; Lacrima, K; Martin, V; Rinaldi, A; Tibiletti, MG; Vignati, S	1

Other Studies

1 other study(ies) available for cyc 202 and Lymphoma, B-Cell

Article	Year
Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leukemia & lymphoma, 2007, Volume: 48, Issue:1 Topics: Aged; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription Factors; Tumor Cells, Cultured	2007

Article

Year

Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.

Leukemia & lymphoma, 2007, Volume: 48, Issue:1

Topics: Aged; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Female; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Protein Kinase Inhibitors; Purines; Roscovitine; Transcription Factors; Tumor Cells, Cultured

2007